Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer
The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.
Breast Cancer
DIAGNOSTIC_TEST: F-Var3 PET/CT|OTHER: Blood draw
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0, The safety of patients will be evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1 and grade 2 toxicities are considered safe., 30 days after completion of study treatment and assessments
The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.